Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Tonix Pharma ( (TNXP) ) is now available.
On April 29, 2026, Tonix Pharmaceuticals announced program updates for its TNX-4800 candidate for Lyme disease prevention and presented Phase 1 data at the 4th Annual Ticks and Tickborne Diseases Symposium. The company reported pharmacokinetic results from the Phase 1 study that it believes support moving TNX-4800 into more advanced clinical testing.
Tonix plans to launch an adaptive Phase 2 field study of TNX-4800 in the first half of 2027, pending agreement from the U.S. Food and Drug Administration. The planned trial will evaluate a fixed two-dose subcutaneous regimen aimed at delivering six months of protection against Lyme disease, underscoring Tonix’s effort to establish a differentiated prophylactic option in the growing tickborne disease market and potentially strengthen its position in infectious disease therapeutics.
The most recent analyst rating on (TNXP) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
The score is held back primarily by very weak profitability and persistent cash burn, alongside bearish technical signals with the stock trading below key moving averages. Offsetting these, the balance sheet is low-debt with a stronger 2025 capital base, and corporate updates (Phase 3/Phase 1 progress and Nasdaq uplisting) provide a positive catalyst backdrop for a clinical-stage biotech.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on developing therapeutics for infectious diseases and other conditions. Its pipeline includes TNX-4800, a monoclonal antibody-based product candidate designed to provide prophylactic protection against Lyme disease, targeting patients at risk of tickborne infections in endemic regions.
Average Trading Volume: 399,076
Technical Sentiment Signal: Sell
Current Market Cap: $182.4M
See more insights into TNXP stock on TipRanks’ Stock Analysis page.